Delamanid: Difference between revisions
Created page with "<div style="float: right;"> thumb|none|400px|This image is provided by the National Library of Medicine.</div> __NOTOC__ {{SI}} {{CMG}} ==Overview==..." |
m Protected "Delamanid": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)) |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 2: | Line 2: | ||
[[File:Delamanid.png|thumb|none|400px|This image is provided by the National Library of Medicine.]]</div> | [[File:Delamanid.png|thumb|none|400px|This image is provided by the National Library of Medicine.]]</div> | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
'''Delamanid''' ([[United States Adopted Name|USAN]], codenamed '''OPC-67683''') is an experimental drug for the treatment of [[multi-drug-resistant tuberculosis]]. It works by blocking the synthesis of [[mycolic acid]]s in ''[[Mycobacterium tuberculosis]]'', the organism which causes tuberculosis, thus destabilising its [[cell wall]]. | '''Delamanid''' ([[United States Adopted Name|USAN]], codenamed '''OPC-67683''') is an experimental drug for the treatment of [[multi-drug-resistant tuberculosis]]. It works by blocking the synthesis of [[mycolic acid]]s in ''[[Mycobacterium tuberculosis]]'', the organism which causes tuberculosis, thus destabilising its [[cell wall]]. | ||
In phase II [[clinical trial]]s, the drug was used in combination with standard treatments, such as four or five of the drugs [[ethambutol]], [[isoniazid]], [[pyrazinamide]], [[rifampicin]], [[aminoglycoside antibiotic]]s, and [[quinolone]]s. Healing rates (measured as sputum [[culture conversion]]) were significantly better in patients who additionally took delamanid. | |||
In phase II [[clinical trial]]s, the drug was used in combination with standard treatments, such as four or five of the drugs [[ethambutol]], [[isoniazid]], [[pyrazinamide]], [[rifampicin]], [[aminoglycoside antibiotic]]s, and [[quinolone]]s. Healing rates (measured as sputum [[culture conversion]]) were significantly better in patients who additionally took delamanid. | The [[European Medicines Agency]] (EMA) recommended conditional marketing authorization for delamanid in adults with multidrug-resistant pulmonary tuberculosis without other treatment options because of resistance or tolerability. The EMA considered the data show that the benefits of delamanid outweigh the risks, but that additional studies were needed on the long-term effectiveness. | ||
The [[European Medicines Agency]] (EMA) recommended conditional marketing authorization for delamanid in adults with multidrug-resistant pulmonary tuberculosis without other treatment options because of resistance or tolerability. The EMA considered the data show that the benefits of delamanid outweigh the risks, but that additional studies were needed on the long-term effectiveness. | |||
==See also== | ==See also== | ||
* [[PA 824]], a related drug | * [[PA 824]], a related drug | ||
| Line 23: | Line 17: | ||
[[Category:Tuberculosis]] | [[Category:Tuberculosis]] | ||
[[Category:Drug]] | [[Category:Drug]] | ||
Latest revision as of 19:39, 18 August 2015
|
WikiDoc Resources for Delamanid |
|
Articles |
|---|
|
Most recent articles on Delamanid |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Delamanid at Clinical Trials.gov Clinical Trials on Delamanid at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Delamanid
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Delamanid Discussion groups on Delamanid Directions to Hospitals Treating Delamanid Risk calculators and risk factors for Delamanid
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Delamanid |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Delamanid (USAN, codenamed OPC-67683) is an experimental drug for the treatment of multi-drug-resistant tuberculosis. It works by blocking the synthesis of mycolic acids in Mycobacterium tuberculosis, the organism which causes tuberculosis, thus destabilising its cell wall. In phase II clinical trials, the drug was used in combination with standard treatments, such as four or five of the drugs ethambutol, isoniazid, pyrazinamide, rifampicin, aminoglycoside antibiotics, and quinolones. Healing rates (measured as sputum culture conversion) were significantly better in patients who additionally took delamanid. The European Medicines Agency (EMA) recommended conditional marketing authorization for delamanid in adults with multidrug-resistant pulmonary tuberculosis without other treatment options because of resistance or tolerability. The EMA considered the data show that the benefits of delamanid outweigh the risks, but that additional studies were needed on the long-term effectiveness.
See also
- PA 824, a related drug